Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Internet Broadcast Project grabs attention of Commonwealth – and yet another award
2015-07-28


 
Learn more about the Internet Broadcast Project and its impact on learners’ lives

The Internet Broadcast Project (IBP) has brought yet another international award to the University of the Free State (UFS). This project – which is changing the lives of Free State school learners – has won second place in the Commonwealth Education Good Practice Awards, a huge achievement considering that the IBP was chosen from 89 submissions entered by a total of 20 countries belonging to the Commonwealth.

This latest award comes close on the heels of another international award that was presented to the IBP recently. In April 2015, the project was the winner of the 2015 Enterprise Video Award (EVA) in the category Video in Education Scholarship. This makes it two in a row, since the IBP also won an EVA in 2014 for Innovation in Pedagogy.

 

Mr Kamalesh Sharma, Secretary General of the Commonwealth Secretariat, presenting the second-place prize for the Commonwealth Good Practice Awards to Sarietjie Musgrave, Head: ICTISE (ICT in School Education) on behalf of ICTISE.
Photo: Peter Ramsay

Live broadcast at no cost to schools
The IBP – presented from the UFS South Campus – makes use of the best teachers to broadcast lessons to school learners who do not have access to quality education. More than 10 subjects are broadcast live, via VSAT Internet Access, to 70 centres across the province. The technology provided at each school allows learners to communicate with the presenter in the studio during broadcast at no cost to the school or learner.

“Through the IBP,” says Sarietjie Musgrave, Head: ICTISE (ICT in School Education), “we aim to bring quality education to each and every learner, regardless of their socio-economic status or geographical location, while delivering cost-effective continuous teacher professional development directly relevant to the Free State community we serve.”

Making a positive difference
The Commonwealth Education Good Practice Awards honour education programmes that have made a positive difference to the status and condition of school children, teachers, or the education system in their countries. The IBP was lauded for its excellence in six of the Action Areas of Good Practices:

• Relevance
• Measurable impact and effect
• Sustainability
• Efficiency and effectiveness
• Community participation
• Replication

“Receiving this international award,” says Musgrave, “shows that we are having an impact worldwide.”

 

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept